# 9th Adriatic and 6th Croatian Congress on Pharmacoeconomics and Outcomes Research: Solutions for improving access to healthcare innovation in CEE region

#### THURSDAY (11 April 2019)

## **Opening ceremony**

14:00 Welcome address by Congress President, Dinko Vitezic

14:10 Welcome address by Congress President, Igor Francetic

14:15 Welcome address by EACPT Past President, Tabassome Simon

14:20 Welcome address by Croatian Ministry of Health

14:30 KEY NOTE SPEECH

Eduard Vrdoljak: Economic evaluation of the Croatian National Cancer Control Plan

15:00 Discussion

15:10 Coffee break

#### National oncology strategies and programs - how patient centric are they? Example of Croatian Cancer Control Plan

#### Chairmen: Igor Francetic, Ingrid Belac Lovasio

15:30 Viktorija Erdeljic-Turk: The future of access to innovative medicines in cancer therapy in Croatia

15:50 Sinisa Varga: 'Members of European Parliament against cancer' - concept and objectives

16:10 Slobodanka Bolanca: Is affordability the only limitation to cancer treatments in CEE?

Round table discussion:

16:30 National oncology strategies and programs - how patient centric are they? Example of Croatian Cancer Control Plan

Moderator: Sinisa Varga

17:45 Closure of Day 1

18:00 Welcome reception

# FRIDAY (12 April 2019)

### Selected pharmacoeconomic and outcomes research studies - what can we learn from them?

Chairmen: Dinko Vitezic, Iva Kraljicković

09:00 Aleksandar Knezevic: Cost comparison of stroke prevention in atrial fibrillation: warfarine vs new oral anticoagulants

09:20 Vanesa Benkovic: The cost of stroke in Croatia

09:40 Tereza Saric: Diabetes care in Croatia - clinical and economic consequences

 ${\tt 10:00~Marta~Kucan:}~ \textbf{Cost effectivenes of antihypertensive drugs-balance of clinical and pharmacoeconomic outcomes}$ 

10:20 Tabassome Simon (key note speech): Can We improve Healthcare decisions making for better patients outcomes in emergecy

departments 10:50 Discussion

11:00 Coffee break

## Fairness and equity in dealing with affordability challenges for new health technologies - any solution on a horizon?

Chairmen: <mark>Tea Strbad, Sinisa Varga</mark>

11:20 Jurij Furst: The systemic payback scheme

11:40 Livio Garattini: Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?

12:00 Anze Droljc: The key to succesful digital transformation

12:20 Stefano Lucherini: Modeling the budget impact and health outcomes of the anti PD-1/PD-L1 class in cancer care in Slovenia

12:40 Neda Vitezic: An Innovative Approach to Measuring Public Health Prevention Outcomes

12:50 Discussion

13:00 Lunch

## Fairness and equity in dealing with affordability challenges for new health technologies - any solution on a horizon? - cont.

Chairmen: Robert Likic, Neda Vitezio

14:00 Slobodan Jankovic: Simple method for adjusting results of pharmacoeconomic studies from country to country using Bayesian statistics

14:20 Petra Dosenovic Bonca: Indirect versus direct economic impacts of ill health: insights from Slovenia

14:40 Barbara Stegel: Pharmaceutical spending trends in Slovenia

15:00 Faris Gavrankapetanovic: Essential lists in F/BIH - equity or equality

15:20 Tanja Novakovic: Solving the Big Data challenge of Medical Scientific Literature

15:40 Discussion

15:50 Coffee break

#### **Pricing & Reimbursement Reform in Croatia - Expected Outcomes?**

(this session will be held in Croatian language)

Chairmen: Dinko Vitezic, Viktorija Erdeljic-Turk

16:10 Tea Strbad: Current situation in pricing and reimbursement in Croatia

16:30 Sani Pogorilic: Future access to breakthrough technologies in Croatia

16:50 Tonci Buble: Generic medicines in Croatia: dillemas for future

Round table discussion:

17:10 Pricing & Reimbursement Reform in Croatia - Expected Outcomes?

Moderator: Dinko Vitezic

18:00 Rountable Conclusion and Closure of Day 2

#### Poster session

Chairmen: Igor Francetic, Slobodan Jankovic

18:00 Arijana Turcin, Robert Likic:

OPTIMIZATION OF PSYCHOPHARMACOTHERAPY IN SCHIZOPRENIA: A CASE REPORT

18:05 Deni Rkman, Kristijan Dominik Rudez, Igor Radanovic, Mijo Babic, Robert Likic, Iveta Mercep:

COMPARISON OF BIOSIMILAR INFLIXIMAB UTILIZATION IN 2018 AT THE LARGEST CROATIAN UNIVERSITY HOSPITAL WITH TRENDS IN OTHER EUROPEAN COUNTRIES

Kristian Dominik Rudez, Deni Rkman, Igor Radanovic, Tina Dusek, Sinisa Cikic, Darko Kastelan, Robert Likic:

COMPARISON OF BIOSIMILAR INSULIN UTILIZATION IN 2018 IN CROATIA WITH REGARDS TO OTHER EUROPEAN COUNTRIES 18:15 Eric Nham, Kristian Dominik Rudez, Deni Rkman, Igor Radanovic, Igor Milovcic, Mato Primorac, Robert Likic:

POTENTIAL COST SAVINGS ACHIEVED THROUGH USE OF ORAL VERSUS INTRAVENOUS ANTIBIOTICS FOR TREATMENT OF SPONDYLODISCITIS IN CROATIA Igor Radanovic, Deni Rkman, Kristian Dominik Rudez, Robert Likic:

18:20 COST-ANALYSIS OF MIRTAZAPINE VS MEGESTROL ACETATE FOR THE TREATMENT OF CANCER-RELATED ANOREXIA/CACHEXIA SYNDROME (CACS): A POTENTIAL FOR A

Sven Plese, Borna Miholic, Dragana Petrovic, Nikolina Bosnjakovic, Lucija Zerec, Tatjana Savoric, Robert Likic, Iveta Mercep:

POTENTIAL FOR SAVINGS THROUGH BETTER CONTROL OF OVERUTILIZATION OF PROTON PUMP INHIBITORS

Marko Boskovic, Robert Likic:

18:30 POTENTIAL FOR SAVINGS THROUGH PATENT EXPIRY ON NOVEL ORAL ANTICOAGULANT

20:30 Congress dinner

## SATURDAY (13 April 2019)

### Importance of patients' informed engagement in healthcare policy decisions

Chairmen: Natalija Petkovic Podiaversek, Bertalan Nemeth

09:00 Ivett Jakab: Patient centricity in health care

09:20 Luka Voncina: Archetypes of patients' involvement in healthcare decision making in CEE

09:40 Marcela Omahen: Patient support programme: value for patients and payer

10:00 Livio Garattini: Patient empowerment in Europe: is no further research needed?

10:20 Ines Potocnjak: Clinical studies - is it worth it?

10:40 Discussion

10:50 Coffee break

### Selected pharmacoeconomic and outcomes research studies - what can we learn from them?

Chairmen: Aleksandar Knezevic, Mirjana Hui

11:10 Robert Likic: Are fixed dose drug combinations pharmacoeconomically sound?

11:30 Krzysztof Landa: How to accelerate uptake of innovative drugs in prioritized medical fields- case study on schizophrenia

11:50 Zoltan Kalo: How to evaluate programs targeting the management of chronic multimorbid patients

12:10 Iva Kraljickovic: Price and cost-effectiveness of new antibiotics

12:30 Stevce Acevski: Pharmacoeconomic aspect on antibiotic consumption in Macedonia in 2016

12:50 Discussion

13:00 Lunch

## Access to orphan drugs: how to reconcile available funding and patients' health needs?

14:00 Bruno Sepodes: Marketing Authorisation and Patient Access to Orphan Medicinal Products: Creating Bridges over Troubled Waters

14:30 Zoltan Kalo: Challenges of funding orphan drugs in CEE

15:00 Dinko Vitezic: Orphan drugs: drug pricing vs incentives

15:30 Discussion

15:40 Coffee break

### New frontiers and paradigmes in health technology assessment in Europe

Chairmen: Jurij Furst, Ivett Jakab

16:00 Miriana Huic: Joint HTA work in EU: Current status and the future

16:20 Pero Draganic: Early Dialogue and a HTA/Payer's perspective in a CEE

16:40 Bertalan Nemeth: Transferability of HTA: present and future trends from the CEE perspective

Round table discussion: Current and future 'HTA / reimbursement assessment' challenges in EU, and CEE 17:00 Moderator: Bertalan Nemeth

## **Congress Closing and Farewell**

18:00 Closing address by Congress President, Dinko Vitezic 18:10 Closing address by Congress President, Igor Francetic

## **SUNDAY (14 April 2018)**

Open Joint Post Congress Meeting of Collaborative Associations - ISPOR, HDKFIT, INIFEZ, UZEFI

10:00 HDKFIT, INIFEZ: Feedback from the 9th Adriatic and 6th Croatian Congress on Pharmacoeconomics and Outcomes Research 10:30 HDKFIT, INIFEZ: Proposal for topics and committees for the 10th Adriatic Congress on Pharmacoeconomics and Outcomes Research 11:00 ALL: Possible joint regional research activities

12:30 Lunch and departures